The experimental drug, Cabaletta, improved muscle function and reduced swallowing difficulty in patients’ suffering from oculopharyngeal muscular dystrophy.

BioBlast said the drug improved patients’ muscle function while also reducing difficulty in swallowing.
Oculopharyngeal muscular dystrophy is a rare disease where patients develop swallowing difficulties, which could lead to death in severe cases.
The company said it would discuss results from this study and a second mid-stage study with the U.S. Food and Drug Administration before it started a late-stage study.
Source-Medindia